Sensei Biotherapeutics, Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a crossroads, balancing a high-potential clinical asset against severe structural and financial risks. The acquisition of PIKTOR and the accompanying $200 million raise have successfully extended the company's life, shifting the immediate narrative from survival to clinical validation. However, the 'going concern' warning and the looming conversion vote for preferred stock create a volatile backdrop for investors. The ultimate outcome for SNSE depends on two factors: the 2026 clinical data for endometrial and breast cancer, and the ability to navigate the complex capital structure without triggering a cash settlement. While the operational lean-down is impressive, the company remains a binary bet on a single mechanism of action in a crowded and fast-moving oncology sector.